VK 2735
Alternative Names: VK-2735Latest Information Update: 16 Oct 2026
At a glance
- Originator Viking Therapeutics
- Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Obesity
- Preclinical Diabetes mellitus
- No development reported Non-alcoholic steatohepatitis
Most Recent Events
- 16 Oct 2026 Viking Therapeutics initiates phase III SUNRISE 2 clinical trials in Obesity at unknown location (PO) (NCT07868939)
- 15 Oct 2026 Phase-III clinical trials in Obesity (PO) (NCT07868835)
- 22 Sep 2026 Efficacy and adverse events data from a phase-I VK2735-102 Maintenance trial in Obesity released by Viking Therapeutics